NCT01381549 - GSK2251052 in Complicated Urinary Tract Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 28, 2011

Primary Completion Date

March 6, 2012

Study Completion Date

March 6, 2012

Conditions

Infections, Urinary Tract

Interventions

DRUG

GSK2251052

Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion

DRUG

imipenem-cilastatin

Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion

OTHER

Placebo

saline placebo

Trial Locations (24)

11527

GSK Investigational Site, Athens

GSK Investigational Site, Goudi, Athens

12462

GSK Investigational Site, Chaïdári

18003

GSK Investigational Site, Granada

28040

GSK Investigational Site, Madrid

28905

GSK Investigational Site, Getafe/Madrid

31059

GSK Investigational Site, Toulouse

51503

GSK Investigational Site, Council Bluffs

56429

GSK Investigational Site, Thessaloniki

66604

GSK Investigational Site, Topeka

75110

GSK Investigational Site, Corsicana

90033

GSK Investigational Site, Los Angeles

92151

GSK Investigational Site, Suresnes

125367

GSK Investigational Site, Moscow

194354

GSK Investigational Site, St'Petersburg

214018

GSK Investigational Site, Smolensk

344022

GSK Investigational Site, Rostov-on-Don

664079

GSK Investigational Site, Irkutsk

G7H 5H6

GSK Investigational Site, Chicoutimi

J1H 5N4

GSK Investigational Site, Sherbrooke

03010

GSK Investigational Site, Alicante

03203

GSK Investigational Site, Elche (Alicante)

Unknown

GSK Investigational Site, Murcia

07010

GSK Investigational Site, Pama de Mallorca